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preservation and avoids permanent colostomy. Aim of this work was to 
give an overview on up-to-date technical possibilities and clinical 
results of the brachytherapy boost treatment in anal canal cancer.  
Material and Methods: A literature review was performed and 
synchronized with personal experience on the field. Special focus was 
taken on image guided (image adapted) interstitial brachytherapy 
methods. Investigated imaging guidance possibilities include the use 
of 3D transrectal ultrasound, MRI- and CT imaging. Preplanning and 
real-time planning methods are discussed. The role of FDG  -PET in 
target definition as well the role of LDR, PDR and HDR brachytherapy 
methods were analyzed in relation to clinical results. Outcome and 
toxicity data were reviewed according to different dose levels and 
techniques. 
Results: Modern external beam technology (IMRT) improves the results 
of radiotherapy w/o chemotherapy. FDG-PET seems to be superior to 
CT in visualization of the primary tumor. Image fusion (PET/MRI /CT) 
can improve the results of a single imaging method; however, 3D 
transrectal ultrasound represents the most appropriate local imaging 
for target definition. Radiation dose is associated with local control in 
locally advanced anal cancer: higher dose and shorter overall 
treatment time (>54 Gy within 60 days) improve the results. Most of 
the studies report local control (LC) rates with anal function 
preservation at five years of >80% in small tumors and ~ 65-70% in 
T3/4 disease. Nodal stage is the most significant factor influencing 
overall survival (~66% at 5 years). PDR appears to be able reproducing 
the good continuous LDR treatment results. Image guided/adapted 
HDR brachytherapy boost complementary to IMRT w/o chemotherapy 
results in moderate decrease of late radiation proctitis data. Usually, 
brachytherapy boost reduce severe acute toxicity of high-dose IMRT 
and offer a low late toxicity rate (18% G3/G4). Controlled QoL 
investigations showed slightly better but not significant differences in 
toxicity of HDR boost compared to IMRT boost - in advantage of 
brachytherapy.  
Conclusions: Interstitial brachytherapy boost complementary to 
external beam treatment is an effective dose escalation method in 
function preservation therapy of anal canal cancers. Total dose level 
and total treatment time are important factors for the outcome. 
Modern, image guided and adapted brachytherapy technology 
compared to careful patient selection has the potential to reduce late 
toxicity and preserve function.  
 
SP-0123   
Modern brachytherapy, an option for head and neck cancers. 
Indications, techniques and results.  
B. Johansson1, L. Karlsson2 
1Örebro University Hospital, Oncology, Örebro, Sweden  
2Örebro University Hospital, Medical Physics, Örebro, Sweden  
 
Introduction: After a golden age (1980-1990) with a lot of 
publications and presentations of Head and Neck (H&N) cancers and 
LDR manual brachytherapy this area has become an increasing silent 
area of brachytherapy (BT). 
This happened despite of the following:  
 Good historical data with high local control rate (LC) and 
preservation of function and anatomy.  
 New emerging technologies (PDR and HDR) with perfect 
radiation protection and improved patient care  
 Improved 3D CT-based dose planning with possibilities for dose 
optimization.  
Materials and Results: Since 1994 PDR BT has been routinely used in 
our hospital as a modern substitute for LDR in the treatment of H&N 
cancers. We present our experience in four different indication groups 
with examples: 
A) Mono brachytherapy for cancer of the Lip (PDR 60Gy for 6 days) 
where we found a 5- year LC of 95 %. In other T1-T2 Squamous or 
Basal cell Carcinomas in the H&N region treated by interstitial or 
surface applications we found a 90% LC rate. 
B) Boost brachytherapy (PDR 35 Gy for 3,5 days) of Base of Tongue 
(BOT) cancer (43% were T3-T4) we obtained 89% LC after 5 years. A 
lot of other areas for BT boost in H&N cancers are also of interest. 
C) Reirradiation of local recurrences. No systematic data available. 
High LC reported but with a significant risk of soft tissue necroses. 
 D) Adjuvant brachytherapy after marginal or non-radical surgical 
resection. No systematic data available. The combined procedure is 
feasible in our experience and should be further investigated in the 
future.  
 
Discussion and conclusions:  In our experience modern machine 
afterloading with PDR is at least as effective as classical LDR BT. 
Systematic data on HDR BT in H&N cancers is sparse but probably is 
similar in effect. 
Modern BT will improve patient care and dose planning. 
Long time follow up with high patient numbers is crucial to study 
these relatively rare tumour sites. International pooled data analyses 
organized by the ESTRO H&N working group are being planned. 
Theoretical education (an ESTRO course) and practical training (at 
several European training sites organized by ESTRO) in modern H&N 
cancer brachytherapy are essential for the future development of this 
area. 
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The ULICE project - Union for Light Ion Centers in Europe - started in 
2009 and it is now in its final phase. In the ULICE community a 
discussion on how to go ahead exploiting the major scientific results 
got from the project research activities is open. The most important 
output will be the creation of a European Hadron Therapy Research 
Board. This structure will be a multi-centres research organisation 
willing to go beyond ULICE. Taking advantage of the network of 
communication and research, both clinical and pre-clinical, 
constructed during the course of the project, it should be feasible to 
continue with exchange of experiences, enhance clinical and 
translational research between current, and future, European Hadron 
Therapy Centers, all of them being partners of the ULICE consortium. 
Mentioned multi-centre international setting can really urge radio-
oncology and hadron therapy in particular to raise a shared clinical 
evidence.   
The main tasks of the building up European Hadron Therapy Research 
Board will be 1) to guide the design, implementation, operation and 
continuous evaluation of a prospective multi-centre database for 
patients treated in a defined consortium of centres with carbon ions, 
protons, advanced photons; 2) to guide the design, performance and 
results of database orientated research; 3) to design, to decide and to 
follow up on multi-centre phase I, II, and III clinical studies performed 
in the carbon-ion centres alone or in combination with photon and/or 
proton facilities; 4) to link translational research from various areas of 
interest and research groups to ongoing and projected clinical trial 
and database orientated research. 
The activities of this European Hadron Therapy Research Board will be 
linked to all relevant clinical radiotherapy research organisations and 
networks on the international/ national/regional level in European 
member states and regions which focus on hadron and advanced 
photon radiotherapy research.  
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MEDRAPET (MEDical RAdiationProtection Education and Training, 
MEDRAPET) is a European Commission project aimed to improve the 
implementation of the Medical Directive’s provisions related to 
radiation protection education and training of medical professionals in 
the EU member states. The professional organizations involved include 
the European Society of Radiology (ESR) as a coordinator, the 
European Federation of Organizations for Medical Physics (EFOMP), 
the European Federation of Radiographer Societies(EFRS), the 
